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Abstract: Squamous cell cancer of the head and neck (SCCHN) is a major contributor to 
morbidity and mortality worldwide. In recent years, inhibition of the epidermal growth factor 
receptor has become an established treatment strategy in SCCHN both in the up-front treatment 
and in the recurrent and metastatic setting. This review summarizes the most important 
developments of the recent past and provides an overview of newer developments.
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Background
Squamous cell cancer of the head and neck (SCCHN) is a major contributor to morbidity 
and mortality and accounts for approximately 5% of all new cancer diagnoses. 
Worldwide, more than 600,000 new cases are diagnosed every year and 350,000 cancer 
deaths can be attributed to this disease.1 The majority of patients are diagnosed in the 
locally advanced and metastatic stages and survival has been poor despite the fact that 
SCCHN is very sensitive to treatment with a high rate of remissions.
As chemotherapy combinations have become increasingly intense in recent 
years, it has become evident that a limit has been reached where gains in activity and 
response rate are offset by greater toxicities.2 Targeted therapies with their different 
side effect profile offer the possibility to further expand and intensify combination 
therapy and numerous trials have explored this strategy in many fields of solid tumor 
oncology including head and neck cancer. The advances in the basic sciences and an 
ever increasing number of potential targets have created a new wealth of therapeu-
tic possibilities that are now explored in various stages of pre-clinical and clinical 
development. In the last few years in particular, progress has been made. However, 
an increasingly comprehensive picture is just beginning to emerge and clinical testing 
remains critical.
Head and neck cancer treatment is also transforming as a result of targeted 
therapies. Among the first potential targets that were recognized in SCCHN was 
the epidermal growth factor receptor (EGFR). It is overexpressed in many types of 
epithelial neoplasms including SCCHN where robust overexpression is found in 90% 
of cases. The EGFR/ErbB1 receptor is a member of the tyrosine kinase superfamily 
along with the other three members of the erbB tyrosine kinase family which include 
erbB2 (HER2/neu), erbB3 (HER3), and erbB4 (HER4).3
The EGFR includes a ligand binding extracellular domain at the N-termial end, 
a transmembrane section that anchors the molecule in the cell membrane and an Cancer Management and Research 2009:1 152
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intracellular domain that transmits signals to a multitude of 
downstream signaling pathways. Upon binding of a ligand 
such as EGF or transforming growth factor-β (TGF-β), 
dimerization of the EGFR occurs and phosphorylation of 
intracellular tyrosine residues trigger activation of the EGFR 
complex and the downstream signaling cascade.4 Among 
the pathways involved in EGFR signal transmission are 
the MAP kinase and the PI3 kinase pathways with their 
downstream effectors, respectively, that control a vast array 
of intracellular processes including cell cycling, cell adhesion 
and migration among others.5–8
Strategies to block activity of the EGFR have been 
explored in the past years and have become an established 
part of modern SCCHN treatment. Inhibition of EGFR 
activity can be achieved through the following main 
methods: 1) through antibody binding to the receptor, which 
interferes with ligand binding and induces internalization 
and subsequent breakdown of the antibody-EGFR complex 
in addition to immunologic events that may result in desta-
bilization of targeted cells, 2) with small molecules that 
act as competitive inhibitors to the intracellular adenosine 
triphosphate (ATP)-binding site, and 3) through specific 
downregulation of the EGFR.
EGFR antibodies
Anti-EGFR chimeric monoclonal antibodies include 
cetuximab (C225, Erbitux®) and fully humanized antibodies 
such as panitumumab, matuzumab, nimotuzumab, and 
zalutumumab. They are specific to the extracellular portion 
of the EGFR and exert their anti-EGFR activity by inhibiting 
ligand binding, thus interfering with EGFR activation. They 
also induce internalization of the EGFR resulting in a lower 
number of EGFR at the cell surface. Furthermore, antibody 
binding may trigger an immunologic response resulting in the 
de-stabilization and ultimately apoptosis of the cancer cell.
Among this class of drugs, cetuximab (Erbitux®) has 
the longest track record and has been studied extensively 
in head and neck cancer. In patients with locally advanced, 
potentially curable SCCHN, data from a randomized trial 
shows that the addition of cetuximab to radiation in the 
definitive treatment of locally advanced SCCHN results 
in improved local control, overall survival and time to 
progression compared with radiation alone.9 In a landmark 
study in 424 patients with stage III and IV squamous cell 
cancer of the oropharynx, hypopharynx, or larynx, the 
median duration of locoregional control was 24.4 months 
among patients treated with cetuximab plus radiotherapy and 
14.9 months among those given radiotherapy (hazard ratio 
for locoregional progression or death, 0.68; P = 0.005). With 
a median follow-up of 54 months, the median duration of 
overall survival was 49 months among patients treated with 
combined therapy and 29.3 months among those treated with 
radiotherapy alone (hazard ratio for death, 0.74; P = 0.03) and 
progression-free survival was increased significantly as well. 
Interestingly, patients with oropharyngeal primary tumors 
enjoyed the greatest benefit compared to other locations 
highlighting biological differences within SCCHN, which 
affect response to treatment and outcomes.
When cetuximab is used as the single agent in metastatic 
disease SCCHN patients, the response rate is modest around 
15%. However, a large, randomized trial tested CDDP/5FU 
with or without the addition of cetuximab in 442 patients 
with overall survival as the primary endpoint. Median 
survival was 7.4 months in the chemotherapy alone arm 
compared to 10.1 months for chemotherapy plus cetuximab 
arm (P = 0.036) which was one of the longest median survival 
times in this patient group ever recorded.10 Side effects 
typically include the acneiforme rash (80% overall, 3% 
severe) and interestingly correlates with a tumor response. 
In contrast, EGFR expression as measured by immunohisto-
chemistry in this study was not a reliable predictor of tumor 
response.11 Allergic reactions are found in approximately 
3% of patients who receive cetuximab and recent evidence 
suggests that reactions at least in some regions of the United 
States are triggered by carbohydrate residues added during 
the manufacturing process.12
Other studies are evaluating cetuximab in combination 
with paclitaxel or docetaxel and promising response rates 
including a significant number of complete responses have 
been reported as abstracts.13 A particularly interesting drug 
combination is based on the observation that up-regulation 
of vascular endothelial growth factor (VEGF) has been 
associated with cetuximab resistance, raising the possibility 
that combined targeting of VEGF and EGFR may enhance 
antitumor activity. The results of a phase II trial using 
cetuximab in combination with the humanized monoclonal 
VEGF antibody bevacizumab in 28 patients with incurable 
head and neck cancer showed a partial response in 20%.14 
Perhaps more importantly this limited analysis also showed 
that the combination was well tolerated and appeared safe 
with no cases of grade 4 bleeding, the most concerning side 
effect given the risk of severe and sometimes fatal bleeding 
in squamous cell cancer of the lung in patients treated with 
bevacizumab. Studies using a similar, but fully humanized 
monoclonal anti-EGFR antibodies such as panitumumab are 
also under way but no data from phase II trials in patients Cancer Management and Research 2009:1 153
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with metastatic disease has yet been published. Other 
ongoing trials with cetuximab include a combination with a 
humanized monoclonal insulin-like growth factor receptor 
(IGFR) antibody IMC A12. Preclinical studies suggest 
synergy between EGF and IGFR inhibition and a high rate 
of cell death was observed. This trial is currently accruing 
patients to explore activity in incurable recurrent or metastatic 
disease patients and no results are available to date.
Other antibody based strategies using toxin-bound 
antibodies directed against the EGFR are currently being 
considered for use in head and neck cancer patients but no 
results are available to date.
EGFR inhibition with small 
molecule tyrosine kinase inhibitors
A number of EGFR-specific agents from the class of the 
small molecule tyrosine kinase inhibitors have emerged 
and are used in a variety of tumors, including SCCHN. 
They are competitive antagonists of the ATP-binding site, 
inhibiting phosphorylation and subsequently activation of 
the EGFR receptor. When used as single agent, the response 
rate appears comparable to that seen with anti-EGFR 
antibodies. Studies led by investigators at the University 
of Chicago evaluated gefitinib (Iressa®) in patients with 
recurrent SCCHN. Fifty-two patients were treated with 
500 mg gefitinib per day and approximately half of the 
patients received gefitinib as second-line therapy. An 
objective response was found in 10.6% and – perhaps more 
interestingly – the disease control rate was 53%. There 
appears to be a dose dependence as the response rate to 
gefitinib at a lower dose (250 mg per day) induces responses 
is only 1.4%.15 A similar agent, erlotinib (Tarceva®), 
been tested in patients with recurrent disease and the 
response rate was 4% with a progression-free survival 
and overall survival similar to that seen with gefitinib.16 
There is some evidence from these trials that response to 
erlotinib may be more likely in patients with a high EGFR 
copy number indicative of EGFR amplification.17 The 
side effect profile of the small molecule tyrosine kinase 
inhibitors are remarkably similar to the EGFR antibodies 
and involve acneiform skin rash, diarrhea, and electrolyte 
disturbances including hypocalcemia and hypomagnese-
mia, which are thought to be directly linked to the blocking 
of the EGFR-dependent renal reabsorption. Combination 
with traditional chemotherapy agents has also been 
tested. Erlotinib combined with cisplatin and docetaxel 
demonstrated a response rate of 67% with 4/43 patients 
achieving a complete response. Median overall survival 
was 11 months (8.61, 22.5, 95% confidence interval) and 
progression-free survival was 6.01 months (4.37, 8.25). 
However, six patients had grade 3/4 febrile neutropenia, four 
patients had grade 3/4 dehydration, three patients had grade 
3 diarrhea, and two patients had grade 3/4 gastrointestinal 
(GI) bleeding.18 Similar to the combination of cetuximab 
with bevacizumab mentioned above, erlotinib has also 
been combined with bevacizumab in a phase I/II trial in a 
total of 48 patients with metastatic SCCHN and improved 
efficacy compared with erlotinib alone was found. Seven 
patients had a response, with four showing a complete 
response. Median overall survival and progression-free 
survival were 7.1 months (95% CI: 5.7–9.0) and 4.1 months 
(95% CI: 2.8–4.4), respectively. The most common side 
effects of any grade were rash and diarrhea (41 and 16 of 
48 patients, respectively) and serious bleeding of grade 3 
or higher occurred in three cases.19
Other small molecule tyrosine kinase inhibitors that 
inhibit a broader range of tyrosine kinases such as vandetanib 
(AZ6474, Zactima®) are also tested in SCCHN. Vandetanib 
was primarily developed as an inhibitor of the VEGF receptor 
but also has significant EGFR-inhibiting properties as well. 
It is currently evaluated in combination with docetaxel and 
no results in SCCHN have been published.
Downregulation of the EGFR by direct injection of anti-
sense DNA is also pursued at specialized centers. Data from 
a phase I trial suggests that this approach is well tolerated 
and tumor responses were seen.20 However, given the scarcity 
of data and the invasiveness of the therapy, this approach 
needs further validation before a broader application could 
be considered.
Drug combinations such as inhibitors of the toll-like 
receptor antagonist along with EGFR inhibitors have been 
tested in cell culture studies and it appears that there may 
be synergy when both pathways are blocked.21 However, no 
clinical studies are currently exploring this strategy in head 
and neck cancer patients.
Summary and outlook
EGFR antagonists have added an invaluable tool to the 
modern medical treatment of SCCHN. While perhaps the 
greatest gains have been made with combining EGFR 
inhibition with radiotherapy in the locally advanced, curable 
stages, anti-EGFR therapy has also become an established 
part of palliative treatment of SCCHN patients. Small 
molecule tyrosine kinase inhibitors also hold promise of 
advancing current treatments given their considerable 
biological activity and their convenient administration.Cancer Management and Research 2009:1
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Despite this progress, formidable challenges remain. The 
identification of tumor and patient characteristics that are 
linked to treatment response are still at early stages in SCCHN 
and future success will depend on a broad effort of clinicians, 
translational and basic scientists. A personalized approach 
to treatment with EGFR inhibitors in SCCHN and cancer 
treatment in general will be critical to achieve cost effective-
ness and maximize clinical impact on patient’s lives.
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